Furthermore, the novel immunomodulatory systemic therapies used successfully for cutaneous melanoma, such as T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody blocker Ipilimumab and Programmed-cell-death-1 (PD-1) inhibitors Nivolumab and Pembrolizumab have also produced uncertain results for uveal melanoma [7,8], with the small-cohort clinical study conducted by Kottschade L.A. et al. reporting varying disease control in half of the patients and progression in the other half [8]. This evidence concerns the gene PDCD1 and cutaneous melanoma.